Who
James Kihara
Principal Accounting Officer
Company insider
Files Form 4 as: Principal Accounting Officer, ACADIA Pharmaceuticals.
In numbers
- Trades disclosed
- 110
- Buys
- 0
- Sells
- 26
- Bought
- $0
- Sold
- $1.8M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 23 Feb 2021
- Last trade
- 26 Jun 2026
- Last filed
- 29 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 Jun 2026filed 29 Jun 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $298K11,421 at $26.08 | filing |
| 26 Jun 2026filed 29 Jun 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $298K11,421 at $26.08 | filing |
| 26 May 2026filed 27 May 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $114K5,401 at $21.18 | filing |
| 26 May 2026filed 27 May 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $114K5,401 at $21.18 | filing |
| 4 May 2026filed 5 May 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $29K1,332 at $21.79 | filing |
| 4 May 2026filed 5 May 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $29K1,332 at $21.79 | filing |
| 1 May 2026filed 5 May 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —2,596 | filing |
| 1 May 2026filed 5 May 2026 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —2,596 at $0.00 | filing |
| 1 May 2026filed 5 May 2026 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —2,596 at $0.00 | filing |
| 1 May 2026filed 5 May 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —2,596 | filing |
| 7 Apr 2026filed 7 Apr 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $23K1,030 at $22.20 | filing |
| 7 Apr 2026filed 7 Apr 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $23K1,030 at $22.20 | filing |
| 5 Apr 2026filed 7 Apr 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —2,010 | filing |
| 5 Apr 2026filed 7 Apr 2026 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —2,010 at $0.00 | filing |
| 5 Apr 2026filed 7 Apr 2026 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —2,010 at $0.00 | filing |
| 5 Apr 2026filed 7 Apr 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —2,010 | filing |
| 26 Mar 2026filed 26 Mar 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $24K1,097 at $21.65 | filing |
| 26 Mar 2026filed 26 Mar 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $26112 at $21.73 | filing |
| 26 Mar 2026filed 26 Mar 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $24K1,097 at $21.65 | filing |
| 26 Mar 2026filed 26 Mar 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $26112 at $21.73 | filing |
News
Head-To-Head Comparison: ACADIA Pharmaceuticals (NASDAQ:ACAD) versus C4 Therapeutics (NASDAQ:CCCC)ACAD · tickerreport.com · 19 Oct 2026Critical Review: ACADIA Pharmaceuticals (NASDAQ:ACAD) and C4 Therapeutics (NASDAQ:CCCC)ACAD · dailypolitical.com · 15 Oct 2026ACADIA Pharmaceuticals (NASDAQ:ACAD) Cut to "Neutral" at UBS GroupACAD · themarketsdaily.com · 13 Oct 2026
0 headlines in the last 90 days name James Kihara; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.